Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omnicell, Inc. (NASDAQ: OMCL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As a publicly traded healthcare technology company focused on intelligent medication management, Omnicell files a range of reports with the U.S. Securities and Exchange Commission that describe its financial condition, risks, governance, and material events.
Investors and researchers can use this page to review Omnicell’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss topics such as revenues from connected devices, technical services, SaaS and Expert Services, and consumables, as well as the company’s strategy to transform into a digitally enabled medication management technology company. Current reports on Form 8-K provide timely updates on matters including quarterly financial results, amendments to bylaws, and the appointment of executive officers.
For users interested in governance and corporate structure, filings detail actions like the adoption of amended and restated bylaws that refine stockholder nomination procedures, address proxy rule requirements, and clarify jurisdictional provisions. Risk factor discussions in Omnicell’s periodic reports outline considerations related to economic conditions, demand for medication management solutions, regulatory and legal obligations, cybersecurity, supply chain, and competition.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of Omnicell’s 10-Ks, 10-Qs, and 8-Ks without reading every page. Real-time updates from EDGAR, combined with structured access to historical filings, allow investors to follow how OMCL’s disclosures evolve over time and to connect regulatory information with the company’s broader narrative in medication management technology.
Omnicell, Inc. is a healthcare technology company focused on autonomous medication management across hospitals, health systems, and outpatient pharmacies. The company combines dispensing automation, robotics, and its cloud-based intelligence ecosystem, OmniSphere, to improve safety, labor efficiency, and financial outcomes from central pharmacy to bedside and retail settings.
Omnicell organizes offerings into hospital and health system solutions, outpatient pharmacy solutions, specialty and 340B services, institutional and retail pharmacy support, and patient engagement under its EnlivenHealth brand. In 2024, U.S. prescription drug spending reached
The company generated approximately
Omnicell VP and Chief Accounting Officer Brian H. Nutt reported routine equity transactions involving company common stock. On February 15, 2026, 258 shares were disposed of to cover tax withholding tied to vesting restricted stock units. The reported balance also reflects 445.6135 shares purchased that day under Omnicell's Employee Stock Purchase Plan, bringing his direct holdings to 17,529.6135 shares.
Omnicell EVP and COO Nnamdi Njoku reported a tax-related share disposition. On February 15, 2026, 1,146 shares of Omnicell common stock were withheld at
After this withholding and an additional 239.4457 shares purchased under the company’s Employee Stock Purchase Plan on
Omnicell, Inc. executive Corey J. Manley reported share dispositions. He sold 4,243 shares of common stock in an open-market transaction at an exact price of $36.59 per share under a Rule 10b5-1 trading plan adopted on June 13, 2025.
Separately, 2,022 shares were withheld to cover taxes due on the vesting of restricted stock units, which is a tax-withholding disposition rather than an open-market sale. After these transactions and the purchase of 87.3392 shares under the Employee Stock Purchase Plan on February 15, 2026, he directly owned 85,496.3392 shares.
OMNICELL, INC. Chairman, President and CEO Randall A. Lipps reported a tax-withholding disposition of 5,294 shares of common stock on
After this transaction, Mr. Lipps directly owned 380,740.0741 shares of Omnicell common stock. He also reported indirect holdings of 355,861 shares held in trust with his wife and 8,051 shares held in trust for the benefit of his children.
Omnicell insider Corey Manley filed a notice to sell common stock under Rule 144. The filing covers 4,243 common shares to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $155,251.37, and an approximate sale date of February 17, 2026.
The shares were acquired on February 15, 2026 through restricted stock vesting as compensation from the issuer. The notice also lists prior sales over the past three months, including multiple common stock transactions by Manley with disclosed share counts and gross proceeds, showing an ongoing program of share dispositions.
Omnicell, Inc. filed a current report stating it issued a press release on February 5, 2026 announcing its financial results for the quarter and year ended December 31, 2025. The press release is provided as Exhibit 99.1 and is furnished, rather than filed, under securities laws.
Omnicell executive Corey J. Manley, EVP & Chief Legal/Admin Officer, sold 6,106 shares of Omnicell common stock on January 8, 2026. The sale was executed at an exact price of $49.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell stock according to preset instructions. After this transaction, Manley beneficially owned 91,674 shares of Omnicell common stock directly.
Omnicell insider Corey Manley has filed a Form 144 notice to sell up to 6,106 shares of Omnicell common stock through Fidelity Brokerage Services on NASDAQ, with an indicated aggregate market value of $304,689.40. The planned sale involves common shares, while Omnicell had 44,876,522 shares of common stock outstanding; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired mainly through restricted stock vesting and an employee stock purchase plan between December 2023 and March 2025, including grants of 3,590 shares on March 1, 2025 and 1,370 shares on August 15, 2024. Over the prior three months before this notice, Manley sold 3,473, 6,106, and 278 shares of Omnicell common stock in separate transactions, receiving gross proceeds of $121,207.70, $243,629.40, and $12,037.40, respectively.
Omnicell, Inc.'s Executive Vice President and Chief Legal/Administrative Officer reported routine share movements. On December 15, 2025, 224 shares of common stock were withheld to cover taxes due on the vesting of restricted stock units. On December 16, 2025, the executive sold 278 shares of Omnicell common stock at an exact price of $43.30 per share.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After these transactions, the executive beneficially owned 97,780 shares of Omnicell common stock, all held directly.